BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us
Archives
  • September 2022
  • August 2022
  • July 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us

Browsing Tag

Gene and Cell Therapy

1 post

When you think of the future, keep in mind that the field of regenerative medicine is rapidly advancing. Cell and gene therapies are a new kind of medicine with enormous potential still to be realized. Most current, small-molecule medicines are made in a standardized way and have a limited lifespan within the body.

Cell and gene therapies are not the same as existing drugs. They entail removing cells, protein, or genetic material (DNA) from the patient (or a donor), modifying them in a personalized way for individual needs before re-injecting them into the patient.

Cell and gene therapies may provide longer-lasting effects than traditional medicines. They have the potential to treat serious illnesses such as motor neuron disease, as well as a variety of uncommon problems for which there are no effective treatments.

Gene Therapy

Gene therapy in its most broad definition is the use of genetic material to cure or treat a disease. The introduced genetic material affects how a single protein or group of proteins is manufactured by the cell.

A variety of diseases have been treated with gene therapy, including muscular dystrophy and Leber’s congenital amaurosis. It can be used to decrease levels of a disease-causing form of a protein, increase production of disease-fighting proteins, or generate new/modified proteins.

Cell Therapy

Cell therapy is the transfer of viable, live cells into a patient to assist with curing or treating an illness. The cells may come from the patient (autologous) or a donor (allogeneic). Cells used in cell therapy can be categorized according to their potential to convert into various cell types. The type of cells administered to the patient depends on the treatment needs.

Cell Therapy vs. Gene Therapy

Cell therapy is a treatment that aims to cure illnesses by regenerating or modifying specific sets of cells, as well as using cells to deliver a drug via circulation throughout the body.

The cells may be fabricated outside the body and then injected into the patient with cell therapy. Autologous cells come from the patient (end autologous), whereas allogeneic cells do not (end allogeneic).

Gene therapy seeks to cure diseases by replacing, inactivating, or introducing genes into cells inside or outside the body (in vivo) or vice versa (ex vivo).

Both cell and gene therapies are referred to as “treatments.” These treatments function by modifying genes in particular sorts of cells and transplanting them into the body. Some therapies are considered both cell and gene therapies.

Capricor CEO to Present at American Society of Gene and Cell Therapy Annual Meeting Ahead of Q1 Earnings Update
BioTech Health X
  • May 13, 2021

Biotech NewsCapricor CEO to Present at American Society of Gene and Cell Therapy Annual Meeting Ahead of Q1 Earnings Update

  • 3 minute read
May 13 is a busy day for biotechnology company Capricor Therapeutics (NASDAQ: CAPR). The company which focuses on…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Virios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results
  • CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
  • Mayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator
  • SyneuRx CEO Dr. Emil Tsai Exclusive Interview with Insights & Projections
  • Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
Recent Comments
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • September 19, 2022
    Virios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results
    Virios-Therapeutics-Stock-Plunges-70-on-Fibromyalgia-Clinical-Trial-Failure-Results
    • September 14, 2022
    CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
    CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
    • September 3, 2022
    Mayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator
    Mayo-Clinic-Gene-Accelerator
    • September 2, 2022
    SyneuRx CEO Dr. Emil Tsai Exclusive Interview with Insights & Projections
    SyneuRx CEO Interview Dr Emil Tsai BioTech Health X
    • August 1, 2022
    Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
    Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
Recent Posts
  • ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
    ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
    • July 28, 2022
  • Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement
    Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement
    • July 22, 2022
  • Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
    Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
    • July 20, 2022
Categories
  • BioTech CEO Interviews (4)
  • Biotech News (44)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by Code Supply Co.
  • Our Contributors
  • List of Modern Life Science Technologies
  • Contact Us
Back to top